| Literature DB >> 34322394 |
Yunshi Cai1, Bohan Zhang1, Jiaxin Li1, Hui Li1, Hailing Liu1, Kunlin Xie1, Chengyou Du2, Hong Wu1.
Abstract
BACKGROUND AND AIMS: Hepatic and coagulation function are routine laboratory tests prior to curative hepatectomy. The prognostic value of gamma-glutamyl transpeptidase (GGT) to platelet ratio (GPR) and international normalized ratio (INR) in surgically treated patients with intrahepatic cholangiocarcinoma (ICC) remains unclear.Entities:
Keywords: GGT to platelet ratio; gamma-glutamyl transpeptidase; international normalized ratio; intrahepatic cholangiocarcinoma; nomogram
Year: 2021 PMID: 34322394 PMCID: PMC8311735 DOI: 10.3389/fonc.2021.711061
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Baseline characteristics of patients.
| Variables | Deveriation set (n=530) | Validation set (n=123) |
|---|---|---|
| Age, mean ± SD | 57.2±10.7 | 58.2±11.1 |
| Gender, n (%) | ||
| Male | 256(48.3%) | 71(57.7%) |
| Female | 274(51.7%) | 52(42.3%) |
| Cirrhosis, n (%) | 148(27.9%) | 16(13.0%) |
| Ascite, n (%) | 50(9.4%) | 60(48.8%) |
| Child score, n (%) | ||
| 5 | 451(85.1%) | 93(75.6%) |
| 6 | 79(14.9%) | 30(24.4%) |
| Multiple tumors, n (%) | 157(29.6%) | 36(29.3%) |
| Tumor size (cm), mean ± SD | 5.9±2.7 | 6.2±1.4 |
| Poor tumor differentiation, n (%) | 336(63.4%) | 90(73.2%) |
| Hepatolithiasis, n (%) | 88(16.6%) | 23(18.7%) |
| Microvascular invasion, n (%) | 53(10.0%) | 15(12.1%) |
| Macrovascular invasion, n (%) | 123(23.2%) | 25(20.3%) |
| Lymph node metastasis, n (%) | 129(24.3%) | 35(28.5%) |
| Biliary invasion, n (%) | 53(10.0%) | 63(51.2%) |
| Perineural invasion, n (%) | 77(14.5%) | 29(23.6%) |
| Liver capsule invasion | 325(61.3%) | 65(52.8%) |
| CA19-9, n (%) | ||
| ≥22U/ml | 138(26.0%) | 30(24.4%) |
| <22U/ml | 346(65.3%) | 93(75.6%) |
| Not available | 46(8.7%) | 0(0%) |
| HBsAg (positive),n(%) | 153(28.9%) | 22(17.9%) |
| HCV, n (%) | 3(0.6%) | 0(0%) |
| TNM stage, n (%) | ||
| I-II | 173(32.6%) | 45(36.6%) |
| III-IV | 357(67.4%) | 78(63.4%) |
| BCLC stage | ||
| 0-A | 268(50.6%) | 47(38.2%) |
| B-C | 262(49.4%) | 76(61.8%) |
| INR grade | ||
| <1.1 | 457(86.2%) | 80(65.0%) |
| ≥1.1 | 73(13.8%) | 43(35.0%) |
| GPR grade | ||
| <0.7 | 354(66.8%) | 55(44.7%) |
| ≥0.7 | 176(33.2%) | 68(55.3%) |
| Overall survival, month, mean ± SD | 24.9±21.4 | 26.2±20.8 |
CA19-9, cancer antigen 19-9; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; BCLC stage, Barcelona Clinic Liver Cancer stage; INR, international normalized ratio; GPR, gamma-glutamyl transpeptidase to platelet ratio.
Univariate and multivariate analyses to determine independent predictors of overall survival.
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Gender, Female/Male | 0.821 | 0.658-1.023 | 0.078 | |||
| Age | 0.995 | 0.987-1.008 | 0.708 | 0.833 | 0.643-1.078 | 0.165 |
| Cirrhosis | 1.274 | 1.002-1.619 | 0.047 | 1.511 | 1.145-1.993 | 0.003 |
| Hepatolithiasis | 1.323 | 1.005-1.751 | 0.046 | 1.344 | 0.976-1.851 | 0.07 |
| Tumor number,Multiple/single | 1.712 | 1.359-2.156 | <0.0001 | 1.587 | 1.074-2.346 | 0.02 |
| Tumor size,≥5/<5(cm) | 1.212 | 0.969-1.517 | 0.092 | 1.237 | 0.941-1.626 | 0.126 |
| Tumor differentiation, Undifferentiation-Poor/Moderate-Well | 2.053 | 1.555-2.712 | <0.0001 | 1.881 | 1.396-2.535 | <0.0001 |
| Microvascular invasion | 1.719 | 1.236-2.391 | 0.001 | 1.009 | 0.696-1.465 | 0.958 |
| Macrovascular invasion | 1.181 | 0.914-1.526 | 0.203 | |||
| Lymph node metastasis | 2.353 | 1.856-2.981 | <0.0001 | 1.775 | 1.326-2.377 | 0.0001 |
| Liver capsule invasion | 1.078 | 0.858-1.352 | 0.517 | |||
| Perineural invasion | 1.564 | 1.161-2.109 | 0.003 | 1.5466 | 1.088-2.197 | 0.015 |
| GPR-INR score | ||||||
| 0 | Reference | Reference | ||||
| 1 | 1.806 | 1.395-2.341 | <0.0001 | 1.436 | 1.059-1.946 | 0.019 |
| 2 | 3.233 | 2.226-4.696 | <0.0001 | 2.794 | 1.833-4.258 | <0.0001 |
| CA199 grade ≥22/<22(U/ml) | 2.166 | 1.621-2.895 | <0.0001 | 2.018 | 1.471-2.769 | <0.0001 |
| HBV | 1.131 | 0.889-1.437 | 0.317 | |||
| HCV | 1.865 | 0.597-5.828 | 0.283 | |||
| TNM stage,III-IV/I-II | 1.397 | 1.075-1.815 | 0.012 | 1.045 | 0.711-1.535 | 0.821 |
| BCLC stage,B-C/0-A | 1.608 | 1.276-2.028 | <0.0001 | 1.201 | 0.874-1.649 | 0.256 |
CA19-9, cancer antigen 19-9; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC stage, Barcelona Clinic Liver Cancer stage; INR, international normalized ratio; GPR, gamma-glutamyl transpeptidase to platelet ratio.
Figure 1The predictive ability of GPR-INR score for OS and RFS in the derivation set. (A, B) The time-dependent AUC curves of GPR, INR and GPR-INR score, the AUROC of the GPR-INR score was higher than that of the GPR and the INR for RFS and OS prediction. (C, D) Kaplan–Meier curves of the patients in the derivation set for OS and RFS, GPR-INR score 1 had better RFS and OS than GPR-INR score 2, worse RFS and OS than GPR-INR score 0.
Figure 2Subgroup analyses using univariable Cox regression to assess the discrimination ability of the GPR-INR score for overall survival and recurrence-free survival in patients with different clinical characteristics. CI, confidence interval.
Figure 3The GPR-INR nomogram. (To use the nomogram, the patient’s value was located on each variable axis, and a line was drawn to determine the individual points. The sum of these points was located on the total points axis, and a line was drawn downward to determine the likelihood of 1-, 3- or 5-year OS). CA-199, preoperative serum CA 19-9 level; LN metastasis, regional lymph node metastasis.
Comparisons of the values of two models in predicting prognosis of overall survivals among the patients in derivation and validation cohort.
| Models | C-index |
|---|---|
| Derivation cohort | |
| GPR-INR score | 0.597 |
| GPR-INR nomogram | 0.708 |
| Validation corhort | |
| GPR-INR score | 0.678 |
| GPR-INR nomogram | 0.746 |
INR, international normalized ratio; GPR, gamma-glutamyl transpeptidase to platelet ratio; C-index, Harrell’s concordance-index.
Figure 4The calibration curves for predicting the OS of the patients at 3 years in the derivation set (A) and validation set (B) and at 5 years in the derivation set (C) and validation set (D). The decision curve analysis for the BCLC staging system, the AJCC 8th TNM system and the GPR-INR nomogram in the derivation set (E) and the validation set (F).